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PK11195Neuroinﬂammation is a major risk factor in Parkinson's disease (PD). Alternative approaches are needed to treat
inﬂammation, as anti-inﬂammatory drugs such as NSAIDs that inhibit cyclooxygenase-2 (COX-2) can produce
devastating side effects, including heart attack and stroke. New therapeutic strategies that target factors
downstream of COX-2, such as prostaglandin J2 (PGJ2), hold tremendous promise because they will not alter
the homeostatic balance offered by COX-2 derived prostanoids. In the current studies, we report that repeated
microinfusion of PGJ2 into the substantia nigra of non-transgenic mice, induces three stages of pathology that
mimic the slow-onset cellular and behavioral pathology of PD: mild (one injection) when only motor deﬁcits
are detectable, intermediate (two injections) when neuronal and motor deﬁcits as well as microglia activation
are detectable, and severe (four injections) when dopaminergic neuronal loss is massive accompanied by
microglia activation and motor deﬁcits. Microglia activation was evaluated in vivo by positron emission
tomography (PET) with [11C](R)PK11195 to provide a regional estimation of brain inﬂammation. PACAP27
reduced dopaminergic neuronal loss and motor deﬁcits induced by PGJ2, without preventing microglia
activation. The latter could be problematic in that persistentmicroglia activation can exert long-term deleterious
effects on neurons and behavior. In conclusion, this PGJ2-induced mouse model that mimics in part chronic
inﬂammation, exhibits slow-onset PD-like pathology and is optimal for testing diagnostic tools such as PET, as
well as therapies designed to target the integrated signaling across neurons and microglia, to fully beneﬁt
patients with PD.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Neuroinﬂammation, particularly microglia and astrocytes, play a
critical role in the pathogenesis of Parkinson's disease (PD) [19,22,
55,84]. A critical factor of neuroinﬂammation is cyclooxygenase-2
(COX-2), which is highly induced in PD and negatively impacts
neuronal function [7,25,40,85]. COX-2 is a key enzyme in the
biosynthesis of prostaglandins, some of which are neuroprotective
while others are neurotoxic [36]. The role of prostaglandins in PDine; DMSO, dimethyl sulfoxide;
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. Figueiredo-Pereira).pathology is poorly deﬁned. In the previous studies we compared
in vitro the neurotoxic effects of four different prostaglandins, i.e.
A1, D2, E2, and J2, and established that prostaglandin J2 (PGJ2) was
the most neurotoxic at the concentrations tested [47].
PGJ2 is derived from PGD2 [87], the principle cyclooxygenase
product synthesized in the mammalian CNS [1,14,30]. From all
prostaglandins, PGD2 levels change the most under pathological
conditions [26,48]. PGD2 readily undergoes non-enzymatic dehydration
to generate PGJ2, which is unique among prostaglandins as it is highly
reactive and forms covalentMichael adducts with cellular proteins [87].
The levels of PGJ2 in the brain are highly elevated in rodent models
of stroke [50,51] and traumatic brain injury (TBI) [31,45], reaching the
100 nM range. These levels represent average brain concentrations,
but it is predicted that local cellular and intracellular concentrations of
PGJ2 could be much higher [52]. Importantly, stroke and TBI increase
the long-term risk for PD [8,35,73,86]. Moreover, PGJ2 impairs the
ubiquitin/proteasome pathway (UPP) [41,47,76,90] and mitochondrial
function [42,43,54], and potentiates dopamine toxicity [64]. Based on
all of these ﬁndings we propose that PGJ2 plays an important role in
PD pathogenesis. In effect, we showed that microinfusing PGJ2 alone
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molecular, cellular and behavioral deﬁcits similar to those in PD [69].
To overcome the neurotoxic effects of PGJ2 we tested the impact of
the pituitary adenylate cyclase-activating polypeptide (PACAP). PACAP
is a potent neuroprotective lipophilic peptide in different models of
neuronal injury such as stroke, Parkinson's disease, Huntington's
disease, traumatic nerve injury, retinal degeneration, and others,
where it exhibits anti-apoptotic, anti-inﬂammatory and anti-oxidant
effects [4,18,53,66,72]. In addition, we previously established that
PACAP prevents neuronal death, proteasome deﬁcits and the decrease
in cAMP levels induced by PGJ2 in vitro [57]. PACAP signals survival
via the activation of the G-protein coupled receptor PAC1R (pituitary
adenylate cyclase 1 receptor), which is expressed in the substantia
nigra pars compacta (SNpc), in the ventral tegmental area (VTA), and
other brain areas [38,81]. Nanomolar concentrations of the two forms
of PACAP, PACAP38 and the truncated form PACAP27 (the latter used
in our experiments), activate adenylate cyclase and elevate intracellular
cAMP [60]. PACAP was shown to mitigate 6-OHDA and MPTP-induced
loss of dopaminergic neurons in animal models of PD [17,71,72,89].
Furthermore, PACAP deﬁciency sensitizes dopaminergic neurons to
paraquat-induced neuroinﬂammation in vivo [92]. Some studies
support the view that PACAP27 is a more potent neuropeptide than
PACAP38 and VIP (vasoactive intestinal peptide) in, for example,
voltage clamped preparations of rat jejunum [15]. Together, these ﬁnd-
ings support our investigation on the efﬁcacy of PACAP27 against the
neurodegenerative effects of PGJ2 with our in vivo model of PD.
Our current study extends our previous one [69], in thatwe establish
progressive stages of pathology induced by four consecutive PGJ2
microinfusions one week apart. These three stages mimic the slow-
onset cellular and behavioral deﬁcits in PD: mild (upon one injection)
when only slight motor deﬁcits are evident, intermediate (upon two
injections) when neuronal and motor deﬁcits as well as microglia
activation are signiﬁcantly detectable, and severe (upon four injections)
when dopaminergic neuronal loss is massive accompanied bymicroglia
activation and motor deﬁcits. We also show that PET imaging of the
brain with [11C](R)PK11195 qualitatively detects microglia activation
induced by PGJ2. Finally, we establish that in the intermediate stage,
PACAP27 protects against neuronal loss and motor deﬁcits, but not in
the severe stage, which most likely coincides with a point of no return.
PACAP27 failed to prevent microglia activation in this rodent model of
PD-like pathology. It is clear that brain injury, initiated in our model
by a neurotoxic product of inﬂammation, involves integrated signaling
across neurons and microglia. Ideally, therapeutic interventions for PD
should target all cells involved regardless of cell type, i.e. neurons
and glia.2. Materials and methods
2.1. Materials
Drugs: PGJ2 (cat. # 18500, Cayman Chemical) in DMSO, and PACAP27
(pituitary adenylate cyclase-activating polypeptide, cat. # H-1172,
Bachem Bioscience) in sterile water. The ﬁnal DMSO concentration
in PBS was 17% for all microinfusions. The solutions were freshly
prepared and stored for a maximum of 2 h at 4 °C and in the dark.
Primary antibodies: dopaminergic neurons [tyrosine hydroxylase
(TH), 1:1000, cat.# MAB318 (mouse) or AB152 (rabbit), Millipore];
GABAergic neurons [GAD67, 1:1,000, cat.# MAB5406 (mouse),
Millipore]; all neurons [NeuN, 1:50, cat.# MAB377 (mouse), Millipore];
microglia and macrophages [Iba1, 1:500, cat.# 019-19741 (rabbit),
Wako Chemicals]; and ubiquitinated proteins [1:200, cat.# Z0458
(rabbit), Dako Cytomation]. Secondary antibodies: Alexa Fluor 568
(1:100, cat.# A11036, rabbit) and Alexa Fluor 488 (1:100, cat.#
A11029, mouse) both from Invitrogen. Vectashield Hard Set™mounting
medium with DAPI (cat.# H-1500, Vector Laboratories).2.2. Mice
Eleven-week old male FVB mice (N = 43; body weight: 25–32 g)
were obtained from Charles River. Mice were singly housed on a 12-h
light/dark cycle, maintained at 23 °C and 50–70% humidity, with food
and water available ad libitum. Mice were allowed to acclimate for
two weeks before surgery. All procedures were performed in
accordance with the NIH Guidelines for the Care and Use of Laboratory
Animals and were approved by the Institutional Animal Care and Use
Committees at Hunter College, CUNY and at Weill Cornell Medical
College.
2.3. Surgery and microinfusion
We followed the sameprocedures as described in our previous study
[69], except that mice received unilateral injections of vehicle (DMSO)
or drugs (PGJ2 and PACAP27) only into the SN. Brieﬂy, at thirteen
weeks of age, mice were anesthetized by isoﬂurane inhalation (induc-
tion 2–2.5%, maintenance 1.5–2%) administered in 100% oxygen and
placed into a stereotaxic frame (Model 51730D, Stoelting Co., Wood
Dale, IL) ﬁtted with a gas anesthesia mask (Model 50264, Stoelting
Co.). A burr hole was drilled in the skull at coordinates relative to breg-
ma for the SNpc [67]: rostral–caudal (RC)=−3.25mm;medial–lateral
(ML)= 1.25mm; and ventral = 4.13mm. All injections were adminis-
tered to the right SNpc, while the contralateral (left) side served as an
internal control. A 2 μL microinjection Hamilton syringe (7002 KH)
with a 25-gauge needle was slowly inserted into the brain and left in
place for ﬁve minutes. Thereafter, 2 μL of solution was infused at an
injection rate of 0.2 μL/min (Quintessential stereotaxic injector, Model
53311, Stoelting Co.). The needle was left in place an additional ﬁve
minutes to ensure total diffusion of the solution. Following injection,
the needle was slowly removed and the incision was closed with
monoﬁlament absorbable sutures (cat. # 033899; Butler Schein Animal
Health, Dublin, OH). After surgery, mice were administered with a
subcutaneous injection of 0.5 cc Lactated Ringer's solution, given wet
palatable rodent chow, and kept in awarmplace to recover. Subsequent
injections to the SNpc were administered via the same drill hole
established during the ﬁrst surgical procedure.
2.4. Groups
Mice were randomly assigned to the treatment groups (Fig. 1). For
behavioral and immunohistochemical analyses, mice in each group re-
ceived either two (2×, n = 3) or four (4×, n = 6) injections of DMSO,
or either one (1×, n=7), two (2×, n=6) or four (4×, n=6) injections
of PGJ2. Moreover, to assess the therapeutic efﬁcacy of PACAP27, other
groups of mice received two injections of PACAP27 (2×, n = 3), or
two injections of PACAP27 + PGJ2 (2×, n = 3) and were compared to
the mice receiving DMSO (2×) or PGJ2 (2×). In preliminary studies
we established that PACAP27 (4×) was ineffective against four PGJ2
injections, thus we did not utilize a 4× PACAP treatment group in our
current paradigm. Behavior was assessed four weeks after the last
microinfusion. Following behavioral assessment, animalswere perfused
intracardially and the brains removed for immunohistochemical
analyses. To obtain maximal signal for μPET imaging, one group of
mice (4×, n = 5) received four unilateral DMSO injections and another
group (4×, n = 5) received four unilateral PGJ2 injections. Mice
underwent μPET scanning one week after the last PGJ2 or DMSO
injection. The concentrations per unilateral injection were 16.7 μg/2 μL
for PGJ2 and 50 ng/2 μL for PACAP27, administered individually or co-
injected. All injections were administered one week apart.
2.5. Behavior
Mice were tested for Parkinsonian-like behavior four weeks after
their last injection (Fig. 1). Scorers were blind to the experimental
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Fig. 1. Schematic representation of the experimental design. Thirteen-week-old male FVB mice were microinjected into the right substantia nigra pars compacta (SNpc) as shown. Mice
received one, two or four microinfusions of either DMSO (control; 17% in PBS), PGJ2 (16.7 μg), PACAP27 (50 ng), or PGJ2 and PACAP27 in 2 μL DMSO/PBS, at weekly intervals as
shown. For all mice motor behavior was assessed four weeks after the last injection. Following behavioral assessment, mice were perfused intracardially and the brains were removed
for immunohistochemical analyses. For in vivo imaging, mice that received four (4×) DMSO or PGJ2 injections underwent micro-positron emission tomography (μPET) scanning one
week after the last injection. n = number of mice per group (gp).
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Inter-scorer reliability was highly correlated (Pearson r N 0.95). There
are batteries of tests that can be used to study PD-related behavioral
changes in rodents [79]. We chose two: 1) Forelimb use asymmetry —
assessed with the cylinder test as in [75]. This test reliably evaluates
spontaneous vertical exploration and limb use asymmetry in a novel
environment [56], which is a sensitive behavioral test used to detect
unilateral damage to the nigrostriatal pathway [75]. Given the unilateral
damage to the SN in our model, we anticipated stronger effects with
asymmetry evaluated with the cylinder test, rather than changes in
spontaneous movement [12]. Limb use asymmetry was expressed as a
ratio of ipsilateral paw over contralateral paw usage and normalized
as percent of the respective control. 2) Curling: this test is used to assess
body axis asymmetry resulting from unilateral damage to the
nigrostriatal pathway [29,56,91], and was performed as in our previous
study [69]. Curling behavior was averaged per group and expressed as a
ratio of curling behavior upon PGJ2 treatment over DMSO treatment.
2.6. Immunohistochemistry
Four weeks after their last microinfusion, mice were terminally
anesthetized (i.p.) with ketamine (100 mg/kg) and acepromazine
(3 mg/kg), and transcardially perfused with 4% paraformaldehyde in
PBS. The mouse brains were removed, post-ﬁxed overnight at 4 °C,
followed by cryoprotection (30% sucrose/PBS at 4 °C). Brains were sec-
tioned in the coronal plane using a freezingmicrotome at a thickness of
30 μm, and sectionswere collected serially along the rostrocaudal axis of
the striatum and substantia nigra pars compacta (SNpc) [between
1.54 mm and −0.10 mm for the striatum, and −2.46 mm and
−3.88 mm for the SNpc; coordinates relative to bregma, as in [67].Tissue series (seven series for the striatum and four series for the
SNpc) were stored at 4 °C (TBS, pH7.4 plus 0.1% sodium azide) until
use. Each series was processed as free ﬂoating sections for immunohis-
tochemical analyses as described in [69].2.7. Stereology
Unbiased stereology analysis was conducted by scorers blind to the
experimental treatments. Total number of TH+, NeuN+, and Iba1+
cells were obtainedwith the Zeiss AxioVision Release 4.8.2 Software un-
biased stereology programming (Carl Zeiss Group, Jena, Germany). Sec-
tions were viewed on an Axio Imager M2 Zeiss microscope (Carl Zeiss
Group) equippedwith amotorized stage and a high resolution AxioCam
MRmRev. 3 camera (Carl Zeiss Group). The outline of the SNpcdelineat-
ed by TH + staining [6] was obtained at low (5×) magniﬁcation, and
sampling of 10 sites per section with the optional fractionator probe,
were averaged. Eight SNpc sections spaced 120 μm apart were used
for the analyses. Cells were counted at 63× along the rostrocaudal
axis, and at predetermined intervals [x-step = 175 μm; y-step =
175 μm; 30,625 μm2; frame associated area (grid size): horizontal =
113.497 μm, vertical = 85.071 μm; 9655.322 μm2]. The z-dimension
was deﬁned as 20 μm, thus providing a 5 μm guard on the top and
bottom surface of each section, for error due to tissue damage.
AxioVision Rel. 4.8 Gundersen coefﬁcients of error were less than
or equal to 0.1. Values obtained were an estimate of cell numbers
in the whole substantia nigra. Dopaminergic (DA) cell counts from
the intact SNpc were similar to a previous report [63]. Care was
taken to ensure that cells within the ventral tegmental area (VTA)
were excluded from SN quantiﬁcation.
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Mosaic images for the SN and striatum were captured with the
AxioVision 4 module MosaiX software, using a Zeiss AxioCam MRm
Rev. camera connected to a motorized stage. A range of 16–24 tiled
images for the SN and 24–30 images for the striatum was captured
at 5×, combined and converted into a TIFF ﬁle.
Densitometry (optical density, O.D.) of the TIFF mosaic images
representing the TH+ terminals in the contralateral and ipsilateral dor-
sal striatumwas performed with the ImageJ software (ImageJ, Rasband,
W.S., ImageJ, U.S. NIH,Maryland, http://rsb.info.nih.gov/ij/, 1997–2006)
as described in [27]. The striatum was divided along the dorsoventral
axis to obtain values speciﬁc for the dorsal striatum, the main region
of the striatum innervated by dopaminergic terminals projecting from
the SNpc [27]. Three tissue analyses per treatment group were used
for quantiﬁcation. Nonspeciﬁc background density was corrected for
by subtracting out completely denervated areas surrounding the
striatum. Data was expressed as O. D. from the ipsilateral dorsal
striatum divided by the contralateral, and normalized as percent to
DMSO control.
2.9. Micro-positron emission tomography (μPET) imaging
μPET imaging was performed using the Inveon trimodal system
(SiemensMedical SolutionsUSA)with a transaxial FOV of approximate-
ly 10 cm and an axial FOV of 12.7 cm. [11C](R)PK11195was synthesized
at the Citigroup Biomedical Imaging Center ofWeill CornellMedical Col-
lege following a published procedure [5]. The radiochemical purity of
the ﬁnal product was N98% with a speciﬁc activity of N13 Ci/μmol. The
dose for imaging the mice ranged from 10 to 30 MBq. Mice were
given a tail vein injection of [11C](R)PK11195 (as a solution of 150–
250 μL saline). Subsequently, mice were anesthetized with isoﬂurane
(2–3% in oxygen) and imagingwas started at 30min after the radiotrac-
er administration. PET scans were acquired for 20 min followed by a
10 min CT scan. [11C](R)PK11195-PET imaging studies were performed
in PGJ2-treated and DMSO-treated mice one week after the last
treatment.
Analysis of the imaging data was performed using the Inveon
ResearchWorkstation (IRW) software (SiemensMedical Solutions). Im-
ages were reconstructed using OSEM3D (2 iterations and 16 subsets),
with a voxel size of 0.78mm× 0.78mm× 0.80mm. Regions of Interest
(ROIs) were deﬁned on summed PET images and Volumes of Interest
(VOIs) were placed on both right and left substantia nigra (SN) and ce-
rebral cortex. Tracer uptake in each VOI was estimated as nanocuries/
cubic centimeters (nCi/cc). Two tracer uptake ratios were determined:
(1) SN lesion (ipsilateral side)/contralateral (intact) SN, and (2) SN
lesion (ipsilateral side)/contralateral cerebral cortex.
2.10. Statistical analyses
All data are expressed as the mean ± SEM. Statistical analyses were
performedwith GraphPad Prism 6 (GraphPad Software, San Diego, CA).
A p-value b 0.05 was considered statistically signiﬁcant. For group
comparisons, we performed one-way analysis of variance (ANOVA)
followed by post hoc Tukey's test for multiple comparison. Correlations
between two variables were evaluated by linear regression calculating
the Pearson correlation coefﬁcients. [11C](R)PK11195 radiotracer
uptake analyses were performed with Student's t test.
3. Results
3.1. Slow-onset dopaminergic neuronal loss in the SNpc/striatum induced
by PGJ2
Using our recently establishedmodel of PD-like pathology,we inves-
tigated in vivo the gradual effects of subchronic inﬂammation. For thispurpose, mice were administered unilateral (right side) injections of
16.7 μg/2 μL PGJ2 to the SNpc for one, two or four weeks (once per
week) as depicted in Fig. 1. Our data show that increasing the weeks
of exposure to PGJ2 progressively intensiﬁed the dopaminergic (DA)
neuronal loss in the SNpc (Fig. 2A and C). The contralateral SNpc served
as theuninjected control. To assessDA speciﬁc damage (Fig. 2A, B and C)
we performed immunohistochemical (IHC) staining for tyrosine
hydroxylase (TH) and for neuron-speciﬁc nuclear protein (NeuN). It is
clear that a single injection of PGJ2 produced no IHC detectable changes
in DA neurons (Fig. 2A, B and C). However, two and four injections of
PGJ2 led to a signiﬁcant decline in DA (TH+) neurons in the SNpc, by
33.4% and 58.7% respectively, compared to DMSO control. The decline
in SNpc DA neurons upon four injections of PGJ2 was signiﬁcantly
greater than that induced by two PGJ2 injections (p b 0.05) supporting
the gradual nature of the PGJ2-induced neuronal loss. No signiﬁcant
differences in TH staining were detected in the contralateral SNpc in
any groups tested (F(3, 8) = 0.78, p = 0.54; Fig. 2A and C). Under all
experimental conditions, the DA neurons in the VTA were spared or
minimally affected (Fig. 2A).
As shown in Fig. 2C, NeuN + immunoreactivity decreased signiﬁ-
cantly following PGJ2 administration [F(4, 11) 20.87, p = 0.0001], thus
corroborating that the loss in TH immunostainingwas due to the degen-
eration of DA neurons and not to TH depletion (Fig. 2B and C).
With four injections of PGJ2 the damage from the SNpc spread to the
striatum, depicted by the decline in TH positive staining (Fig. 3). Optical
density (O.D.) analysis of TH+ terminals at the dorsal striatum showed
that four injections of PGJ2 led to a signiﬁcant TH + terminal loss as
compared to all other conditions [F(3, 8) = 17.19, p = 0.0008, Fig. 3A
and B]. Pearson correlation coefﬁcients indicate a signiﬁcant positive
correlation between the number of ipsilateral TH + cells in the SNpc
and TH + O.D. in the dorsal striatum (r2 = 0.69, p= 0.0009; Fig. 3C).
This analysis supports a positive correlation between the loss of TH
staining in the ipsilateral SNpc and TH terminal loss in the dorsal
striatum upon PGJ2 administration.
3.2. Accumulation of ubiquitinated proteins induced by PGJ2 microinfusion
One of the hallmarks of PD is the accumulation/aggregation of
ubiquitinated proteins in Lewy bodies [21]. This aspect of PD was ad-
dressed in our study. We established that compared to DMSO,
microinfusion of PGJ2 increased the levels of aggregate-like ubiquitin
conjugates in the DA neurons of the SNpc (Fig. 4A and B). More DA neu-
rons exhibiting increased levels of ubiquitinated proteinswere detected
in the SNpc of mice that received two than four PGJ2 injections, because
more DA neurons survived in the former mice. Fig. 4B shows the
distribution of the aggregate-like ubiquitin conjugates under high
magniﬁcation, in mice injected 4× with PGJ2.
3.3. PGJ2 administration increases microglia activation in the SNpc
The rise in activated microglia due to PGJ2 administration was
statistically signiﬁcant (F(4, 12) = 9.55, p = 0.001), as detected by
immunostaining for Iba1 (Fig. 5A and B). The number of activated
microglia in the SNpc was initially ~1800 (uninjected, contralateral
side) and increased gradually, parallel to the number of PGJ2 injections,
reaching more than 7000 upon four PGJ2 injections. The increase in
activated microglia was signiﬁcant upon two and four PGJ2 injections
(at least p b 0.01; Fig. 5B). In addition, there was a signiﬁcant negative
correlation between TH + and Iba1+ cell numbers in the ipsilateral
SNpc (r2 = 0.35, p = 0.043, Fig. 5C). Due to the surgical procedure,
intranigral injection of DMSO alone also increased microglia activity
and so did one PGJ2 injection, but these changes did not reach statistical
signiﬁcance as compared to the contralateral SNpc (Fig. 5B).
A major hallmark of microglial activation is the expression of the
peripheral benzodiazepine receptor, also known as the translocator
protein TSPO [13]. The levels of TSPO are very low in the brain, and
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injury [13]. The isoquinoline carboxamide PK11195 is selective for
TSPO and displays nanomolar binding afﬁnity, thus being ideal for
imaging microglia activation [5]. To obtain a regional estimation of
brain inﬂammation in vivo, we evaluated microglia activation in
the mice by performing micro positron emission tomography
(μPET) with the radioligand [11C](R)PK11195. To obtain maximal
signal, μPET sessions were performed one week following four
DMSO or PGJ2 injections.The brain distribution and uptake of [11C](R)PK11195 in the PGJ2
and DMSO treated mice based on imaging studies, are depicted in
Fig. 5D. The data in the graphs are presented as two tracer uptake ratios:
top graph – ipsilateral (injected) SN/contralateral (intact) SN; bottom
graph – ipsilateral (injected) SN/contralateral cerebral cortex (Ctx). It
is clear that [11C](R)PK11195 uptake was qualitatively more
pronounced in PGJ2 than in DMSO-injected mice conﬁrming that PGJ2
induces microglia activation. The tracer uptake trend was consistent for
the ipsilateral SN/contralateral SN ratio: 2.31 ± 0.32 for PGJ2-treated
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for the ipsilateral SN/contralateral Ctx ratio: 1.76 ± 0.14 for PGJ2-treated
mice versus 1.42 ± 0.11 for DMSO-treated mice (Fig. 5D, bottom graph).
However, in both cases the difference between the two groups (DMSO
and PGJ2-treated) failed to reach statistical signiﬁcance (p = 0.11, top
graph; p = 0.08, bottom graph). We followed microglia activation at
9 weeks after the fourth injection, and the difference between PGJ2 treat-
ment compared toDMSOwas still evident (ipsilateral SN/contralateral SN
ratio: p= 0.06; ipsilateral SN/contralateral Ctx ratio: p= 0.09, studies in
progress).3.4. PGJ2 injected mice gradually develop Parkinsonian-like motor deﬁcits
Clinically, PD is characterized by the presence of motor deﬁcits
caused by the loss of dopamine from dysfunctional dopaminergic
neurons in the substantia nigra [9,23,33]. To establish the effect of PGJ2
administration on motor performance we used two behavioral tests:
the cylinder test which assesses limb use asymmetry, i.e. the rodent's
preference for using the ipsilateral over the contralateral paw
(Fig. 6A), and the curling test which establishes postural instability
(Fig. 6B). The results demonstrate that injection of even a single dose
of PGJ2, upon which there are no statistically signiﬁcant changes in DA
neurons (Fig. 2B and C), results in behavioral abnormalities when
comparing PGJ2 and DMSO groups (Fig. 6A and B).Weekly PGJ2 administration induced a gradual and signiﬁcant
bias toward use of the ipsilateral over the contralateral paw (F(3, 21) =
7.79, p= 0.0011; Fig. 6A), and postural instability consistent with a
unilateral lesion (F(3, 19) = 38.47, p = 0.0001; Fig. 6B). Pearson
correlation coefﬁcients indicate a signiﬁcant negative correlation
between ipsilateral paw use and the number of ipsilateral TH + cells
in the SNpc (r2 = 0.34, p= 0.048; Fig. 6C), as well as a negative trend
between ipsilateral paw use and TH + O.D. in the dorsal striatum
(r2 = 0.26, p = 0.13; Fig. 6D). To address the effects of PGJ2 on
spontaneous vertical exploration, we tested if PGJ2 altered rearing
behavior in the mice, but no signiﬁcant differences in free rears
were observed (F(3, 21) = 0.59, p = 0.63, data not shown).3.5. PACAP27 prevents dopaminergic neuronal loss and motor deﬁcits
induced by PGJ2
Activating cAMP signaling is known to be neuroprotective [78] and
to have a positive effect on the UPP [34], which in contrast is inhibited
by PGJ2 [41,47,76,90]. Therefore, we explored if increasing intracellular
cAMP with PACAP27 would prevent neuronal loss induced by PGJ2. We
chose to co-administer the two drugs, as we recently demonstrated
in vitro that when combined with PACAP27, PGJ2 retains its full
biological activity toward the accumulation of ubiquitinated proteins
in cortical neuronal cultures [52]. Thus the two drugs in concentrated
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established that PACAP27 was not protective in mice receiving four
PGJ2 injections. We thus investigated the neuroprotective effects of
PACAP27 in mice that received two PGJ2 injections. It is clear that
co-administration of PGJ2 (16.7 μg) and PACAP27 (50 ng) signiﬁcantly
reduced DA neuronal loss in the SN (Fig. 7A, B and C). In PGJ2-treated
mice, the number of DA neurons in the ipsilateral SNpc declined signif-
icantly compared to those in DMSO or PACAP27 injected mice, or in the
contralateral (intact) SNpc (F(4, 12) = 7.76; p = 0.003; Fig. 7B). Co-
administration of PGJ2 and PACAP27 prevented the loss of DA neurons
induced by PGJ2 (p b 0.05; Fig. 7B). Moreover, there was no statistical
difference between the number of DA neurons in the contralateral SNpc
and in the ipsilateral SNpc of DMSO, PACAP27 or PGJ2 + PACAP27
injected mice, further supporting the neuroprotective effect of
PACAP27. Similar results were obtained with NeuN staining (Fig. 7C).
PGJ2 caused a signiﬁcant decrease in NeuN+ neurons in the ipsilateral
SNpc when compared to all control groups aswell as tomice co-treatedwith PGJ2 + PACAP27 (F(4, 11) = 48.37, p = 0.0001; Fig. 7C). In
conclusion, PACAP27 prevents the loss of DA neurons induced by PGJ2
administration in vivo. In contrast, GABAergic neurons in the SNpr
region were not affected by PGJ2 microinfusion (Fig. 7A).
The immunohistochemical and behavioral analyses are in agree-
ment. Forelimb use asymmetry and posture stability assessed with
the cylinder test and curling test respectively, were signiﬁcantly
altered by PGJ2 (F(2, 12)= 4.52; p= 0.035, for forelimb use asymmetry;
F(2, 9) = 61.94; p = 0.0001, for postural stability). Two injections of
PGJ2 signiﬁcantly increased ipsilateral forelimb usage (Fig. 7D,
p b 0.05) and posture instability (Fig. 7E, p b 0.001), as compared to
the controls. Co-treatment with PACAP27 prevented the PGJ2-induced
motor deﬁcits (Fig. 7E, p b 0.001) to the point that there was no signif-
icant difference between control and PGJ2 + PACAP27 treated mice.
DMSO and PACAP27 treated mice exhibited similar behaviors (data
not shown) and thuswere combined for behavioral analyses and consid-
ered as the control group.
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proteins nor microglia activation induced by PGJ2
Co-treatment with PACAP27 failed to diminish the accumulation
of ubiquitinated proteins (Fig. 8A) as well as microglia activation
(Fig. 8B), both of which induced by two PGJ2 injections as seen in
Figs. 4A and 5A, respectively. Microglia activation was assessed by
immunostaining with Iba1. While PGJ2 administration (2×) in-
creased microglia activation in the ipsilateral SNpc compared tothe contralateral SNpc, co-treatment with PACAP27 failed to pre-
vent this PGJ2 effect (F(4, 12) = 5.26; p = 0.01, p b 0.05; Fig. 8B).
Furthermore, there was no signiﬁcant difference between mice
that received PGJ2-injections alone and in combination with
PACAP27.
The ﬁnding that PACAP27 was unable to prevent the accumulation
of ubiquitinated proteins and microglia activation induced by PGJ2,
further supports that the two drugs do not combine to form inactive
complexes.
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This study establishes a correlation between successive administra-
tions of PGJ2 tomimic in part chronic inﬂammation, and progressiveDA
neuronal loss in the rodent nigrostriatal pathway. As we analyzed the
mice upon one, two and four weekly substantia nigra microinfusions,
we observed that PGJ2 alonewas sufﬁcient to induce gradualmolecular,
cellular and behavioral deﬁcits reminiscent of PD pathology. Therefore,
PGJ2 is likely to play an important role in mediating the downstream
negative effects of COX-2 in PD. Our previous work established that
four microinjections of PGJ2 into the SNpc and striatum of mice led to
Parkinsonian-like pathology in a PGJ2-concentration dependent
manner [69]. We now show that increasing the number of weeks of
exposure to PGJ2 to mimic subchronic inﬂammation intensiﬁes DA
neuronal loss in the SNpc in a parallel manner. Even upon a single
injection of PGJ2, when there is no apparent change in neurons assessed
by immunostaining for TH and NeuN, there is evidence of SN damage
supported by behavioral motor deﬁcits. Increasing the number of PGJ2
injections induced spreading of the damage from the SNpc to the stria-
tum, and gradual microglia activation. Due to its slow-onset, this mouse
model extends upon our previous ﬁndings by providing an effective
means for identifying earlymolecularmechanisms linked to a particular
behavior due to basal ganglia functional deﬁcits. Complete dopaminer-
gic denervation in animal models of PD are particularly well suited for
the advanced stages of the disorder when alteration in plasticity [11],
loss of striatal dendritic spines [2,16], and changes of glutamatergic
signaling [10,68] are identiﬁed. However, in the advanced stages of
the disease, it is too late to target many of the subtle differences in the
disease state that could play a signiﬁcant role in remediation and in
the development of new therapeutics. Understanding the molecular
changes underlying the early stages of the disease can be facilitatedwith the PGJ2-induced mouse model, in which the gradual progression
of the disorder can be manipulated and a distinction between behavioral
and neuronal deﬁcits is apparent.
The early clinical symptoms of PD are only detected when N70% of
DAneurons is already lost [24]; thusmore robust detection tools are ur-
gently needed. The close inﬂammation–neuronal loss relationship
yields considerable interest and unmet need for the detection (imag-
ing) and follow-up of neuroinﬂammation. Positron emission tomogra-
phy (PET) based on radiopharmaceuticals such as [11C](R)PK11195
that selectively target microglia, the mediators of neuroinﬂammation,
have already shown potential in pre-clinical studies utilizing neuroin-
ﬂammation induced by toxins such as α-amino-3-hydroxy-5-methyl-
4-isoxazolepropionate (AMPA), lipopolysccharide (LPS), 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP), and methamphetamine
(METH), and also in some pilot clinical studies [88]. We now show for
the ﬁrst time (to our knowledge) that μPET imaging with [11C](R)
PK11195 can be used to qualitatively assess changes inmicroglia activa-
tion in the PGJ2-induced mouse model of PD. Microglia activation is
mediated by extrinsic factors (e.g. CD200, CX3CR1, and TREM2) as
well as intrinsic factors (e.g.,Runx-1, Irf8, and Pu.1) [39], and astrocytes
play an important role in regulating microglia activation [77]. The
mechanisms by which PGJ2 induces microglia activation are still un-
known. We previously established that PGJ2 increases the levels of the
pro-inﬂammatory cytokine interleukin-1 (IL-1) in neuronal cells [46].
Considering that IL-1 mediates microglia activation in LPS-injected
mice [83], it is plausible that the PGJ2-induced microglia activation is,
in part, mediated by IL-1. Increases in IL-1 levels are relevant to PD
pathogenesis, as its levels are high in the brains of PD patients compared
to healthy controls [58], and in PD animal models [44,70].
PGJ2 exerts its action via receptor-mediated and receptor-
independent signaling. On the one hand, PGJ2 signals via the Gi coupled
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injury [28,49]. On the other hand, PGJ2 and its metabolites have a
cyclopentenone ring with reactive α,β-unsaturated carbonyl groups
that form covalent Michael adducts with free sulfhydryls in cysteine
residues in glutathione and cellular proteins [80,87]. Endogenous com-
pounds such as PGJ2 that forms covalent bonds with proteins through
electrophilic attack on side chains, such as that of the sulfhydryl group
of cysteine, are regarded as playing an important role in determining
whether neuronswill live or die [74]. The covalent proteinmodiﬁcation
by PGJ2 in the brain represents a novel pathologic post-translational
change and could play a critical role in neurodegeneration in PD [32].
To overcome the PGJ2-induced deﬁcits we tested PACAP27 as it
provides DA neuroprotection in models of PD [71]. Furthermore,
PACAP has a relative low molecular weight, is lipophilic, and crosses
the blood–brain barrier [20]. The simultaneous administration of PGJ2with PACAP27 had two contrasting outcomes. On the one hand, it
signiﬁcantly reduced the level of DA neuronal loss in the SN as well as
the behavioral motor deﬁcits. On the other hand, it failed to prevent
the accumulation/aggregation of neuronal ubiquitinated proteins as
well as microglia activation. These in vivo studies provide the proof-
of-principle that PACAP27 has potential as a therapeutic strategy to
target mechanisms leading to neuronal loss assessed by TH staining
and associated motor deﬁcits, but not for mechanisms controlling
ubiquitin-protein accumulation/aggregation or microglia activation. In
the previous in vitro studies with neuronal cultures we also observed
that PACAP27 failed to diminish the accumulation/aggregation of
ubiquitinated proteins induced by PGJ2 [57].
PACAP27 binds to a range of receptors at various concentrations and
activates a variety of secondmessengers that are dependent not only on
the receptor and G-proteins but also on a repertoire of accessory
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PGJ2-induced mouse model in the future studies, but one of the
pathways by which PACAP signals survival is via activation of the
G-protein coupled receptor PAC1R (pituitary adenylate cyclase 1 receptor).
We previously showed in vitro, that PGJ2 lowers neuronal cAMP
while PACAP raises neuronal cAMP [57]. In addition, PACAP27
prevented some but not all of the neurotoxic effects of PGJ2 [57].
There are several factors that could contribute to the lack of protec-
tion by PACAP27. In regard to the ubiquitinated proteins, PGJ2 im-
pairs the UPP by targeting different components of this pathway
including (a) the 26S proteasome by perturbing its assembly [65,
90] and oxidatively modifying the S6ATPase (Rpt3) subunit [37],
(b) inhibiting de-ubiquitinating enzymes [41,47,50,61], and (c)
causing the accumulation/aggregation of ubiquitinated (Ub) pro-
teins [51]. It is likely that PACAP27 can override the negative effect
of PGJ2 on the proteasome because several components of the UPP
are up-regulated by the activation of the cAMP signaling [34], includ-
ing proteasome subunits, thus leading to an increase in proteasomeactivity [62]. However, PACAP27 may be unable to protect UPP com-
ponents such as UCH-L1 and other de-ubiquitinating enzymes,
which are covalently modiﬁed at speciﬁc cysteine residues by PGJ2
[41,61].
The ﬁnding that PACAP27 failed to prevent microglia activation
induced by PGJ2 could be attributed to a mechanism supported by ani-
mal studies, in that besides being mediators of acute inﬂammation,
prostaglandins also function in the transition and maintenance of
chronic inﬂammation, thus inducing long-lasting effects [3] that may
be refractory to short-term rises in cAMP levels. Persistent Ub-
aggregates and microglia activation could eventually exert deleterious
effects on neurons and behavior. It is known that individuals that suffer
mild brain injuries early in life, may exhibit pathology at a much older
age. Ourmodelwould be ideal to address the potential long term effects
of persistent protein accumulation/aggregation and chronic inﬂamma-
tion in the aging brain.
In conclusion, we demonstrate that consecutive infusions of PGJ2
into the substantia nigra of mice to mimic in part chronic inﬂammation,
1718 K.-Y. Shivers et al. / Biochimica et Biophysica Acta 1842 (2014) 1707–1719induce a slow-onset of Parkinsonian-like neuronal andmotor deﬁcits, as
well as microglia activation. The latter can be imaged in vivo by μPET
with [11C](R)PK11195. We also show that the protection by PACAP27
observed over the short term (two weeks) was sufﬁcient to prevent
neuronal loss and behavioral deﬁcits induced by PGJ2, while microglia
activation persisted. If not halted, the latter could lead to chronic inﬂam-
mation with long-term effects resulting in gradual neurodegeneration,
like in PD. Developing successful anti-inﬂammatory drugs that
potentially target prostaglandin signaling downstream of COX-2, could
be accelerated by non-invasive molecular imaging techniques, such as
PET, that can monitor regional responses in order to effectively assess
early remediation therapies designed to provide overall neuronal and
glial beneﬁts for patients with PD.
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